Juncture Wealth Strategies LLC lifted its stake in shares of Axon Enterprise, Inc. (NASDAQ:AXON) by 6.1% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,890 shares of the biotechnology company’s stock after purchasing an additional 282 shares during the period. Juncture Wealth Strategies LLC’s holdings in Axon Enterprise were worth $856,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds also recently added to or reduced their stakes in AXON. Cullen Frost Bankers Inc. acquired a new position in shares of Axon Enterprise in the 2nd quarter worth approximately $31,000. Credit Agricole S A purchased a new stake in shares of Axon Enterprise in the 2nd quarter valued at approximately $35,000. Berman Capital Advisors LLC grew its position in shares of Axon Enterprise by 73.9% in the 3rd quarter. Berman Capital Advisors LLC now owns 240 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 102 shares during the last quarter. TCI Wealth Advisors Inc. purchased a new position in shares of Axon Enterprise in the 2nd quarter valued at $43,000. Finally, IFP Advisors Inc purchased a new position in Axon Enterprise during the 3rd quarter worth $43,000. 75.45% of the stock is owned by institutional investors and hedge funds.
Several analysts recently commented on AXON shares. Needham & Company LLC raised their price objective on shares of Axon Enterprise from $190.00 to $250.00 and gave the company a “buy” rating in a research note on Friday, August 6th. Craig Hallum upgraded shares of Axon Enterprise from a “hold” rating to a “buy” rating and set a $232.00 target price for the company in a report on Tuesday, November 16th. Robert W. Baird raised their target price on shares of Axon Enterprise from $195.00 to $220.00 and gave the company an “outperform” rating in a report on Friday, August 6th. Raymond James raised their target price on shares of Axon Enterprise from $200.00 to $223.00 and gave the company a “strong-buy” rating in a report on Friday, August 6th. Finally, Zacks Investment Research upgraded shares of Axon Enterprise from a “strong sell” rating to a “hold” rating in a report on Monday, October 11th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Axon Enterprise has an average rating of “Buy” and a consensus price target of $208.43.
Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings results on Monday, November 15th. The biotechnology company reported $1.17 EPS for the quarter, topping analysts’ consensus estimates of $0.26 by $0.91. Axon Enterprise had a negative net margin of 2.37% and a negative return on equity of 2.26%. The business had revenue of $231.99 million during the quarter, compared to the consensus estimate of $201.11 million. During the same period in the previous year, the firm posted ($0.01) earnings per share. The company’s quarterly revenue was up 39.4% compared to the same quarter last year. As a group, analysts expect that Axon Enterprise, Inc. will post -0.85 EPS for the current fiscal year.
In related news, CEO Patrick W. Smith sold 7,237 shares of the business’s stock in a transaction that occurred on Thursday, November 18th. The shares were sold at an average price of $180.15, for a total value of $1,303,745.55. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Patrick W. Smith sold 329,952 shares of Axon Enterprise stock in a transaction that occurred on Tuesday, November 16th. The shares were sold at an average price of $186.25, for a total transaction of $61,453,560.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 594,445 shares of company stock valued at $109,519,770. 2.30% of the stock is owned by insiders.
Axon Enterprise Company Profile
Axon Enterprise, Inc engages in the development, manufacturing, and sale of conducted electrical weapons for personal defense. It operates through the TASER Weapons and Software and Sensors segments. The TASER Weapons segment sells conducted electrical weapons, accessories, and other related products and services.
Recommended Story: Cash Asset Ratio
Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axon Enterprise, Inc. (NASDAQ:AXON).
Receive News & Ratings for Axon Enterprise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axon Enterprise and related companies with MarketBeat.com's FREE daily email newsletter.